MNPR
NASDAQMonopar Therapeutics Inc.
News · 26 weeks43-33%
2025-11-022026-04-26
Mix1690d
- SEC Filings7(44%)
- Insider4(25%)
- Other3(19%)
- Leadership1(6%)
- Offering1(6%)
Latest news
25 items- SECSEC Form DEFA14A filed by Monopar Therapeutics Inc.DEFA14A - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form DEF 14A filed by Monopar Therapeutics Inc.DEF 14A - Monopar Therapeutics (0001645469) (Filer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Presents Phase 3 Data Showing Greater Neurologic Benefit with ALXN1840 vs SoC in Wilson Disease Patients with Neurologic Symptoms at AAN 2026WILMETTE, Ill., April 19, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar" or the "Company") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, announced new analyses from the randomized controlled Phase 3 FoCus trial of ALXN1840 (tiomolibdate choline, TMC) showing greater neurologic benefit versus standard of care (SoC) in Wilson disease patients with neurologic symptoms at baseline. The data will be presented today at the American Academy of Neurology (AAN) Annual Meeting 2026, taking place April 18-22, 2026. In a late-breaker oral and poster presentation titled "Greater clinical benefit with t
- INSIDERSEC Form 4 filed by Robinson Chandler4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 4 filed by Cittadine Andrew4 - Monopar Therapeutics (0001645469) (Issuer)
- SECAmendment: SEC Form 10-K/A filed by Monopar Therapeutics Inc.10-K/A - Monopar Therapeutics (0001645469) (Filer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- SECSEC Form 10-K filed by Monopar Therapeutics Inc.10-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Reports Fourth Quarter and Full-Year 2025 Financial Results and Provides Business UpdateWILMETTE, Ill., March 27, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. ("Monopar," the "Company," "we") (NASDAQ:MNPR), a clinical-stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the fourth quarter and full-year 2025 financial results and provided a summary of recent developments. "2025 was a productive year for Monopar, marked by multiple ALXN1840 data presentations, an important publication, a strengthened balance sheet and continued progress toward a planned New Drug Application submission for ALXN1840 in Wilson disease," said Chandler Robinson, MD, Chief Executive Officer of Monopar. "We also recently strengt
- INSIDERSEC Form 4 filed by CCSO Rodriguez Susan4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 3 filed by new insider Rodriguez Susan3 - Monopar Therapeutics (0001645469) (Issuer)
- SECMonopar Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Monopar Therapeutics (0001645469) (Filer)
- PRMonopar Expands Leadership Team with Appointment of Seasoned Biopharma Executive Susan Rodriguez as Chief Commercial and Strategy OfficerWILMETTE, Ill., March 02, 2026 (GLOBE NEWSWIRE) -- Monopar Therapeutics Inc. (NASDAQ:MNPR) ("Monopar" or the "Company"), a clinical‐stage biopharmaceutical company developing innovative treatments for patients with unmet medical needs, today announced the appointment of Susan Rodriguez as Chief Commercial and Strategy Officer, effective immediately. In this newly created executive role, Ms. Rodriguez will lead the Company's commercial strategy and infrastructure build-out as Monopar prepares for the planned submission of a New Drug Application ("NDA") to the U.S. Food and Drug Administration ("FDA") in the first half of 2026 for ALXN1840, its late-stage investigational therapy for Wilson d
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Monopar Therapeutics Inc.SCHEDULE 13G/A - Monopar Therapeutics (0001645469) (Subject)
- INSIDERChief Executive Officer Robinson Chandler acquired 62,815 shares (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- ANALYSTMorgan Stanley initiated coverage on Monopar Therapeutics with a new price targetMorgan Stanley initiated coverage of Monopar Therapeutics with a rating of Overweight and set a new price target of $115.00
- INSIDERChief Executive Officer Robinson Chandler converted options into 8,724 shares and covered exercise/tax liability with 2,558 shares, increasing direct ownership by 8% to 85,718 units (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERChief Operating Officer Cittadine Andrew converted options into 4,326 shares and covered exercise/tax liability with 1,889 shares, increasing direct ownership by 5% to 50,726 units (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERSEC Form 4 filed by Acting Chief Medical Officer Rioux Patrice4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERChief Financial Officer Vu Quan Anh bought $104,925 worth of shares (1,500 units at $69.95) (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- SECSEC Form 144 filed by Monopar Therapeutics Inc.144 - Monopar Therapeutics (0001645469) (Subject)
- INSIDERDirector Klausner Arthur J sold $343,889 worth of shares (5,121 units at $67.15), decreasing direct ownership by 37% to 8,762 units (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
- INSIDERLarge owner Hendricks Diane disposed of 43,499 shares (SEC Form 4)4 - Monopar Therapeutics (0001645469) (Issuer)
MNPR FAQ
7 questionsWhat does Monopar Therapeutics Inc. do?
Monopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing proprietary therapeutics to enhance clinical outcomes for cancer patients in the United States. It is involved in developing Validive, a clonidine mucobuccal tablet that is in Phase 2b/3 clinical trial for the treatment of radiation induced severe oral mucositis in oropharyngeal cancer patients; Camsirubicin, a topoisomerase II-alpha targeted analog of doxorubicin engineered to retain anticancer activity and for minimizing toxic effects on the heart, which is in Phase 2 clinical trial; and MNPR-101, a...Where does MNPR stock trade?
Monopar Therapeutics Inc. (MNPR) is listed on NASDAQ.What sector and industry is MNPR in?
Monopar Therapeutics Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Monopar Therapeutics Inc. go public?
Monopar Therapeutics Inc. (MNPR) completed its IPO in 2019.What are analysts saying about MNPR?
Monopar Therapeutics Inc. has had 8 recent analyst actions on file. The most recent action was from Morgan Stanley: Overweight on 2026-01-09.What companies are similar to MNPR?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), NVS (Novartis AG). Compare MNPR side-by-side with any of them on Quantisnow.How can I track MNPR on Quantisnow?
Quantisnow aggregates Monopar Therapeutics Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow MNPR to receive live email and push alerts on every new disclosure.